Tracheobronchopathy From Inhaled Corticosteroids
- PMID: 28864055
- PMCID: PMC6026226
- DOI: 10.1016/j.chest.2017.08.013
Tracheobronchopathy From Inhaled Corticosteroids
Erratum in
-
Errors in Table 1 in: Tracheobronchopathy From Inhaled Corticosteroids.Chest. 2019 Jan;155(1):246. doi: 10.1016/j.chest.2018.11.012. Chest. 2019. PMID: 30616735 Free PMC article. No abstract available.
Abstract
Inhaled corticosteroids (ICSs) have become the mainstay of asthma control. They are also recommended as an add-on therapy to long-acting beta agonists and anticholinergics in moderate to severe COPD with recurrent exacerbations. Ultimately this clinical practice has led to the widespread use of ICSs, which are supported by a more favorable side effect profile than that of systemic steroids.
Keywords: excessive dynamic airway collapse; inhaled corticosteroids; tracheobronchomalacia; tracheomalacia.
Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Figures








References
-
- Centers for Medicare and Medicaid Services, Medicare Drug Spending Dashboard 2015. Office of Enterprise Data & Analytics (OEDA), 2016. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Tren.... Accessed July 19, 2017.
-
- National Asthma, Education, and Prevention Program, Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma—summary report 2007. J Allergy Clin Immunol. 2007;120(5 suppl):S94–S138. - PubMed
-
- Sharafkhaneh A., Southard J.G., Goldman M., Uryniak T., Martin U.J. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257–268. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases